Anaheim, CA – July 31, 2026 – Biotime, a leading innovator in the field of in vitro diagnostics (IVD), is pleased to announce its participation in the upcoming Association for Diagnostics & Laboratory Medicine (ADLM) 2026 Annual Meeting & Clinical Lab Expo. The event, the world's premier gathering for laboratory medicine, will take place from July 28-30, 2026 at the Anaheim Convention Center in California, USA.

Biotime will be exhibiting at Booth 845, where the company will demonstrate its commitment to advancing global healthcare through accessible and reliable diagnostic solutions . As a company with a robust portfolio of over 50 patents and a strong investment in research and development, Biotime continues to solidify its position as a trusted partner for laboratories worldwide .

At ADLM 2026, Biotime will spotlight its cutting-edge technology platforms designed to meet the diverse needs of modern clinical laboratories:

• Chemiluminescence Immunoassay (CLIA) Platform: Featuring high sensitivity and high throughput, this automated system is ideal for medium- to large-scale laboratories seeking precision and efficiency.

• Fluorescence Immunoassay (FIA) Platform: Offering flexibility and user-friendly operation, this platform is perfectly suited for point-of-care testing (POCT) and primary care settings.

Built upon these core technologies, Biotime has developed a comprehensive test menu addressing critical disease areas, including cardiovascular risk assessment, diabetes management, infectious disease detection, and autoimmune and inflammatory markers.

"We are thrilled to bring our latest IVD innovations to the global stage in Anaheim," said a spokesperson for Biotime. "ADLM provides an unparalleled opportunity to connect with the global laboratory community. We look forward to demonstrating how our reliable, user-friendly diagnostic solutions can streamline workflows and elevate patient care."

Biotime invites all lab directors, distributors, and clinicians to visit Booth 845 for live product demonstrations, technical consultations, and to explore new partnership opportunities. The company is dedicated to fostering collaborations that will advance the future of laboratory medicine and expand access to quality diagnostics